Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

103 results about "Lung metastasis" patented technology

What is a Lung Metastasis A lung metastasis is a cancerous growth in the lung that got its start from cancer cells originating somewhere else in the body. Cancer cells that spread to and take root in the lungs are said to have “metastasized” the lung.

Pharmaceutical composition having function cancer of the lungs against

A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC50 can reach 26.73 ug/ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.
Owner:TIANJIN UNIV

Albumin-loaded manganese dioxide and perflubron nanoparticles as well as preparation method and application thereof

The invention discloses albumin-loaded manganese dioxide and perflubron nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biology, and the albumin-loaded manganese dioxide and perflubron nanoparticles are prepared from bovine serum albumin-loaded manganese dioxide and perflubron. The invention further provides a preparation method of the albumin-loaded manganese dioxide and perflubron nanoparticle and application of the albumin-loaded manganese dioxide and perflubron nanoparticle in tumor bimodal imaging and enhancement of high-intensity focused ultrasound tumor immunogenic death. The invention has the advantages that the albumin-loaded manganese dioxide and perflubron nanoparticles obtained by the preparation method have the characteristics of enhancing high-intensity focused ultrasound immune death and biocompatibility and being high in active targeting enrichment amount in tumors, and tumor diagnosis and real-time monitoringcan be realized through CT and MRI bimodal imaging; by enhancing high-intensity focused ultrasound tumor immunogenic death, tumor growth and lung metastasis can be inhibited in vivo, and the survivalrate of animals can be increased.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof

The invention provides a cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling the blood coagulation factor VIII level to play an anti-tumor role, and application of the cyclopentanopolyhydrophenanthrene skeleton compound to preparation of drugs for treating blood coagulation factor VIII-mediated tumors, in particular to drugs for treating a blood coagulation factor VIII-mediated tumor which is blood coagulation factor VIII-mediated liver cancer. Experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit expression and secretion of HUVEC endothelial cells FVIII, inhibit HUVEC endothelial cell FVIII mediated hepatoma carcinoma cell proliferation, and inhibit adhesion of tumor cells and platelets mediated by FVIII secreted by HUVEC cells, and in-vivo experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit lung metastasis of liver cancer by inhibiting the level of FVIII.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

RAB22A-NoeFs fusion gene system for diagnosing and/or treating osteosarcoma, and application thereof

The invention discloses a fusion gene line RAB22A-NoeFs for diagnosing and / or treating osteosarcoma. The first and second exons of the RAB22A gene are fused with the 54408036th to 54476718th positionof chromosome 20 after being inversed, the fusion gene line includes the following six fusion genes: RAB22A-NoeF1, RAB22A-NoeF2, RAB22A-NoeF3, RAB22A-NoeF4, RAB22A-NoeF5 and RAB22A-NoeF6, and the nucleotide sequences of the fusion genes are sequentially represented by SEQ ID NO:1-6. The six fusion genes of the fusion gene line RAB22A-NoeFs can promote the migration and invasion of osteosarcoma cells, wherein the RAB22A-NoeF1 has above functions, and also can promote the lung metastasis of the osteosarcoma cells. The fusion gene line RAB22A-NoeFs can be used as a specific therapeutic target forosteosarcoma, and has a great application prospect.
Owner:SUN YAT SEN UNIV CANCER CENT

Use of Liriope muscari Bailey C in pharmacy

The invention belongs to the field of pharmacy, and discloses the application of rusogenin fucopyranoside C in the pharmacy. The invention also provides the application of the rusogenin fucopyranoside C in the preparation of the medicine for resisting tumor metastasis, and more particularly relates to the application in the preparation of the medicine for generating tumour new blood vessels and inhibition of relative tumor metastasis. Being proved by the study of the invention, the rusogenin fucopyranoside C can effectively inhibit the growth, migration and adhesive ability, can inhibit lung metastasis of melanoma B16, and provides new selection in the application of preparing the medicine for resisting tumor metastasis.
Owner:TIANJIN TASLY PHARMA CO LTD

A medicinal preparation for treating breast cancer and preparation method thereof

The present invention belongs to the field of traditional Chinese pharmaceutics, which relates to a traditional Chinese medicinal preparation for treating breast cancer and preparation method thereof.The present invention adopts supplementing qi, nourishing yin, regulating the thoroughfare and controlling vessels as therapeutic principle, which adopts the extracts of the following traditional Chinese medicine raw materials: radix astragali, Radix Codonopsis, bighead atractylodes rhizome, wolfberry, adenophora tetraphylla, epimedium sagittatum, Cornus officinalis, and auxiliary material to prepare a small preparation for treating breast cancer. By animal experiment and clinic trial, the results show that the preparation particles of the present invention can inhibit tumor growth and lung metastasis of tumor-bearing mice and enhance body antitumor enhance host anti-tumor immunity; the clinical studies showed that preparation particles of the present invention can obviously decrease sideeffects caused by a medicament for treating breast cancer and auxiliary treating endocrine, reduce adverse event, improve depression, and anxiety symptoms, and improve life quality of patient. The preparation of the present invention has the advantages of convenient administration, little dosage, no toxic side effect even long-term administration, and good evaluation.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

Mouse model with lung metastasis of gastric cancer and establishment method thereof

The invention relates to a mouse model with lung metastasis of gastric cancer and an establishment method thereof, and belongs to the technical field of experimental animals. According to the mouse model and the establishment method thereof, BGC-823 and MKN-45 gastric cancer cells are cultured in vitro, and resuspended to a proper concentration with sterile PBS when the cell viability is strong. After the cells are cultured inside the body of immunodeficient NUDE and SCID mice inoculated in immunodeficience through the caudal vein, the mouse model with lung metastasis of gastric cancer is successfully obtained by the identifications including the statistics of surface lung nodules, HE staining and IHC staining. According to the mouse model establishment, needed experimental conditions and operation are simple and convenient, lung metastasis lesions after the experiment are obvious, metastasis efficiency is high, and mice with metastatic lesions have moderate survival cycles. In the evaluation and statistics of the metastasis results, the macroscopic counting of the lung nodules is improved into the microscopic counting of the IHC staining positive cells, thereby obtaining more objective and accurate results. The animal model of tumor metastasis may be widely used in scientific research and teaching.
Owner:JIANGSU UNIV

Hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof

ActiveCN105061533AObvious migrationApparent aggressivenessSugar derivativesSugar derivatives preparationOncologyColon cancer cell
The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.
Owner:FUZHOU UNIV

Angiopoietin-like 4 and its use in modulating cell leakiness

Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin [alpha]5[beta]1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin [alpha]5[beta]1-mediated Rac1/PAK signaling to weaken cell-cell contacts. Subsequently, cANGPTL4 is associated with and declusters VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption. In vivo vascular permeability and metastatic assays performed using ANGPTL4-knockout and wild-type mice injected with either control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induced vascular leakiness and facilitated lung metastasis in mice. Therefore, our findings elucidate how cANGPTL4 induces endothelial disruption. Our findings have direct implications for targeting cANGPTL4 to treat cancer and other vascular pathologies.
Owner:NANYANG TECH UNIV

Anti-human YKL-40 neutralizing monoclonal antibody as well as preparation and application thereof

The invention relates to the technical field of medical bioengineering, in particular to an anti-human YKL-40 neutralizing monoclonal antibody. The amino acid sequence of a heavy chain variable regionof the monoclonal antibody is shown as SEQ ID NO:1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO:2. According to the invention, uniquesequence information of the monoclonal antibody is provided, and a hybridoma cell strain secreting the monoclonal antibody and application of the monoclonal antibody and the hybridoma cell strain inpreparation of drugs for inhibiting lung metastasis of liver cancer are also provided.
Owner:中国人民解放军海军军医大学第三附属医院

Calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and prodrug of natural drug

The invention relates to the field of pharmaceutical preparations, and relates to a calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and a prodrug of a natural drug and a preparation method for the nano-drug co-delivery system. According to the nano-drug co-delivery system, nanoparticles prepared from a biodegradable lipid material are taken as carriers, and the phosphorylated prodrug PIC-POOH of the natural drug piceatannol (PIC) is physically entrapped, and the low molecular weight heparin (LMWH) adsorbs on the outer layers of the carriers by static electricity; and a nano preparation concentrates at a tumor site by utilizing the long circulating performance of the nano preparation and the enhanced permeability and retention (EPR) effect ofa solid tumor tissue, a related pathway for tumor cell metastasis is then regulated, angiogenesis is inhibited, and the anti-tumor metastasis action is exerted. Proved by assays, the nano-drug co-delivery system can inhibit the epithelial-mesenchymal transition (EMT) progress of tumor cells; proved by a tube formation assay, the nano-drug co-delivery system can significantly inhibit tumor angiogenesis; proved by in vivo administration evaluation, the nano-drug co-delivery system can reduce formation of lung metastasis on a mice model, and prolongs the survival time of tumor-bearing mice; and the nano-drug co-delivery system has an obvious anti-tumor metastasis effect, especially reduces triple negative breast cancer metastasis, and has high safety.
Owner:FUDAN UNIV

Pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state, and preparation method and application thereof

ActiveCN113384695AExcited state lifetime is longIncreased singlet oxygen quantum yieldOrganic chemistryPhotodynamic therapyQuantum yieldCancer cell
The invention provides a pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state and a preparation method and application thereof. The photosensitive dye has a structure shown in a general formula I. The pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state can have relatively high singlet oxygen quantum yield and relatively long lifetime of excited state. Under the excitation of near-infrared light, the photodynamic killing can be carried out on normoxic and hypoxic cancer cells. Meanwhile, the pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state possesses a good application prospect in the aspects of treating solid tumors in vivo and inhibiting lung metastasis of cancer cells.
Owner:DALIAN UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products